The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis
MAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the course of psoriatic arthritis. Currently, the best-known class of biological drugs is the inhibitors of the proinflammatory cytokine TNF-α,...
Gespeichert in:
| Veröffentlicht in: | Current pharmaceutical biotechnology Jg. 24; H. 2; S. 330 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
01.01.2023
|
| Schlagworte: | |
| ISSN: | 1873-4316, 1873-4316 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | MAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the course of psoriatic arthritis. Currently, the best-known class of biological drugs is the inhibitors of the proinflammatory cytokine TNF-α, including adalimumab.
The aim of this study was to assess changes in the expression of MAP kinase genes in patients with psoriatic arthritis treated with adalimumab, as well as to determine which of the analyzed transcripts could be used as a diagnostic or therapeutic target.
An analysis was performed on the total RNA extracted from PBMCs of patients with psoriatic arthritis before and after three months of adalimumab therapy as well as from a control group. Changes in the expression of the mitogen-activated protein kinase genes were assessed using the HG-U133A 2.0 oligonucleotide microarray method, while the obtained results were validated using the real-time RT-qPCR method.
Using the oligonucleotide microarray method, 14 genes coded for proteins from the MAPK group were identified with at least a two-fold change of expression in the control group and during adalimumab therapy. Validation of the results confirmed a statistically significant decrease in the transcriptional activity of the MAP2K2 gene in the group of patients three months after the administration of adalimumab relative to the control group.
Adalimumab therapy alters the expression of MAPK-coding genes. The assessment of the number of MAP2K2 mRNA molecules can potentially be used in diagnostic analyses or in monitoring adalimumab therapy. |
|---|---|
| AbstractList | MAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the course of psoriatic arthritis. Currently, the best-known class of biological drugs is the inhibitors of the proinflammatory cytokine TNF-α, including adalimumab.
The aim of this study was to assess changes in the expression of MAP kinase genes in patients with psoriatic arthritis treated with adalimumab, as well as to determine which of the analyzed transcripts could be used as a diagnostic or therapeutic target.
An analysis was performed on the total RNA extracted from PBMCs of patients with psoriatic arthritis before and after three months of adalimumab therapy as well as from a control group. Changes in the expression of the mitogen-activated protein kinase genes were assessed using the HG-U133A 2.0 oligonucleotide microarray method, while the obtained results were validated using the real-time RT-qPCR method.
Using the oligonucleotide microarray method, 14 genes coded for proteins from the MAPK group were identified with at least a two-fold change of expression in the control group and during adalimumab therapy. Validation of the results confirmed a statistically significant decrease in the transcriptional activity of the MAP2K2 gene in the group of patients three months after the administration of adalimumab relative to the control group.
Adalimumab therapy alters the expression of MAPK-coding genes. The assessment of the number of MAP2K2 mRNA molecules can potentially be used in diagnostic analyses or in monitoring adalimumab therapy. MAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the course of psoriatic arthritis. Currently, the best-known class of biological drugs is the inhibitors of the proinflammatory cytokine TNF-α, including adalimumab.BACKGROUNDMAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the course of psoriatic arthritis. Currently, the best-known class of biological drugs is the inhibitors of the proinflammatory cytokine TNF-α, including adalimumab.The aim of this study was to assess changes in the expression of MAP kinase genes in patients with psoriatic arthritis treated with adalimumab, as well as to determine which of the analyzed transcripts could be used as a diagnostic or therapeutic target.OBJECTIVEThe aim of this study was to assess changes in the expression of MAP kinase genes in patients with psoriatic arthritis treated with adalimumab, as well as to determine which of the analyzed transcripts could be used as a diagnostic or therapeutic target.An analysis was performed on the total RNA extracted from PBMCs of patients with psoriatic arthritis before and after three months of adalimumab therapy as well as from a control group. Changes in the expression of the mitogen-activated protein kinase genes were assessed using the HG-U133A 2.0 oligonucleotide microarray method, while the obtained results were validated using the real-time RT-qPCR method.METHODSAn analysis was performed on the total RNA extracted from PBMCs of patients with psoriatic arthritis before and after three months of adalimumab therapy as well as from a control group. Changes in the expression of the mitogen-activated protein kinase genes were assessed using the HG-U133A 2.0 oligonucleotide microarray method, while the obtained results were validated using the real-time RT-qPCR method.Using the oligonucleotide microarray method, 14 genes coded for proteins from the MAPK group were identified with at least a two-fold change of expression in the control group and during adalimumab therapy. Validation of the results confirmed a statistically significant decrease in the transcriptional activity of the MAP2K2 gene in the group of patients three months after the administration of adalimumab relative to the control group.RESULTSUsing the oligonucleotide microarray method, 14 genes coded for proteins from the MAPK group were identified with at least a two-fold change of expression in the control group and during adalimumab therapy. Validation of the results confirmed a statistically significant decrease in the transcriptional activity of the MAP2K2 gene in the group of patients three months after the administration of adalimumab relative to the control group.Adalimumab therapy alters the expression of MAPK-coding genes. The assessment of the number of MAP2K2 mRNA molecules can potentially be used in diagnostic analyses or in monitoring adalimumab therapy.CONCLUSIONAdalimumab therapy alters the expression of MAPK-coding genes. The assessment of the number of MAP2K2 mRNA molecules can potentially be used in diagnostic analyses or in monitoring adalimumab therapy. |
| Author | Krawczyk, Agata Kimsa-Dudek, Magdalena Wcisło-Dziadecka, Dominika Juszczyk, Karol Strzałka-Mrozik, Barbara Gola, Joanna |
| Author_xml | – sequence: 1 givenname: Agata surname: Krawczyk fullname: Krawczyk, Agata organization: Department of Nutrigenomics and Bromatology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland – sequence: 2 givenname: Barbara surname: Strzałka-Mrozik fullname: Strzałka-Mrozik, Barbara organization: Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland – sequence: 3 givenname: Karol surname: Juszczyk fullname: Juszczyk, Karol organization: Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland – sequence: 4 givenname: Magdalena surname: Kimsa-Dudek fullname: Kimsa-Dudek, Magdalena organization: Department of Nutrigenomics and Bromatology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland – sequence: 5 givenname: Dominika surname: Wcisło-Dziadecka fullname: Wcisło-Dziadecka, Dominika organization: Department of Cosmetology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland – sequence: 6 givenname: Joanna surname: Gola fullname: Gola, Joanna organization: Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35762548$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUDtPwzAYtFARfcBfQGZjCdifHccZqwIF0YoOZY7sxGkNiVNsZ-i_J4giMd1J99DppmjkOmcQuqHkDmjG7ymTORBKgAkhAIgASSkVnJ-hCZUZSzijYvSPj9E0hA9CgEgJF2jM0kxAyuUE1du9wev5Bl4BL40zWAW86aJx0aoGP1i1c12ItsRr5T-Nx9bhdeds7Lx1OzyvVGPbvlUaDz1eHY64q_EmDKr6Cc193HsbbbhE57Vqgrk64Qy9Pz1uF8_J6m35spivEp0SGRMNZZXXVUo5k5wLU4LJ6rLS2nBiyDBYl6koNVMlzbOqUrnIqlQPwJXhnAHM0O1v78F3X70JsWhtKE3TKGe6PhQgJJWUUZIO1uuTtdetqYqDt63yx-LvG_gGzORp-A |
| CitedBy_id | crossref_primary_10_1016_j_yexmp_2024_104951 crossref_primary_10_1080_15384101_2024_2335051 |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/1389201023666220628111644 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4316 |
| ExternalDocumentID | 35762548 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Medical University of Silesia in Katowice, Poland grantid: PCN - 2 - 048 / N / 0 / I, PCN - 1 - 024 / N / 1 / I |
| GroupedDBID | --- .5. 0R~ 29F 36B 4.4 53G 5GY AAEGP ABEEF ABJNI ACGFS ACITR ACIWK ACPRK ACZAY AENEX AFRAH AFUQM AGJNZ ALMA_UNASSIGNED_HOLDINGS ANTIV C1A CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P GH2 HZ~ IPNFZ KCGFV NPM O9- P2P RIG 7X8 ABMOS AFHZU AGQPQ |
| ID | FETCH-LOGICAL-b508t-b2cd9fd51438446ec2e7fcdbbe40e0548bc56cb3ac197dda967d5ba964ae44322 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000943036100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1873-4316 |
| IngestDate | Thu Jul 10 17:03:48 EDT 2025 Thu Jan 02 22:53:01 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | MAPK2 psoriatic arthritis MAPK adalimumab gene expression anti-TNF |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b508t-b2cd9fd51438446ec2e7fcdbbe40e0548bc56cb3ac197dda967d5ba964ae44322 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35762548 |
| PQID | 2681813105 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2681813105 pubmed_primary_35762548 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current pharmaceutical biotechnology |
| PublicationTitleAlternate | Curr Pharm Biotechnol |
| PublicationYear | 2023 |
| SSID | ssj0020882 |
| Score | 2.3516781 |
| Snippet | MAP kinases are some of the cascades that are specialized in the cell's response to external stimuli. Their impaired functioning can be observed during the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 330 |
| SubjectTerms | Adalimumab - pharmacology Adalimumab - therapeutic use Antirheumatic Agents - adverse effects Arthritis, Psoriatic - diagnosis Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - genetics Cytokines Humans MAP Kinase Kinase 2 Tumor Necrosis Factor-alpha - genetics |
| Title | The MAP2K2 Gene as Potential Diagnostic Marker in Monitoring Adalimumab Therapy of Psoriatic Arthritis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35762548 https://www.proquest.com/docview/2681813105 |
| Volume | 24 |
| WOSCitedRecordID | wos000943036100011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGFKSnDiaTZZKTFLUI2pJDhd5KZkMPTWrTCv33vpek9iQIXpLDMMkw8-a97-2E3Do28lIbugywtWW-F4YM5LzD_Ch2ApA5UquyZP6rGAyi0ShOaoNbUYdVrnhiyah1rtBGfsdDEC0ugJHgfvrJsGsUelfrFhqbpOEBlEGqFqMfLwJH-IgKVyQ8hinfO6SFoc8Awu_QP4eOYA6rCznHTEK49QAOfkeapcTp7f93rQdkr8aatFsRxyHZMNkRaSdVseplhw7XuVdFh7Zpsi5jvTwmFoZpv5vwF06xODVNC5rkc4wugo8-ViF6MJViuo-Z0Y-MVgwCLYW0qwHgTxaTVNa_WdLc0qSAUawRi4t6L-spnZC33tPw4ZnVXRmYBDA3Z5IrHVuNQCsCXdIoboRVWkrjOwYAYCRVECrppcqNhdZpHAodSHj5qfF94B-nZCvLM3NOqKtVKIWJ_Rj0TDcwkTGApriSjhVWek6TtFb7OwaqR1dGmpl8UYzXO9wkZ9UhjadVeY6xByoUqL3RxR9mX5Jd7B9f2VSuSMPCnTfXZFt9wQbMbkpygucg6X8DjujS8g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+MAP2K2+Gene+as+Potential+Diagnostic+Marker+in+Monitoring+Adalimumab+Therapy+of+Psoriatic+Arthritis&rft.jtitle=Current+pharmaceutical+biotechnology&rft.au=Krawczyk%2C+Agata&rft.au=Strza%C5%82ka-Mrozik%2C+Barbara&rft.au=Juszczyk%2C+Karol&rft.au=Kimsa-Dudek%2C+Magdalena&rft.date=2023-01-01&rft.eissn=1873-4316&rft.volume=24&rft.issue=2&rft.spage=330&rft_id=info:doi/10.2174%2F1389201023666220628111644&rft_id=info%3Apmid%2F35762548&rft_id=info%3Apmid%2F35762548&rft.externalDocID=35762548 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-4316&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-4316&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-4316&client=summon |